$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924017037 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$53.00K
YoY Change	-100.0%	-97.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.426M	$4.138M
YoY Change	-6.5%	2.86%
% of Gross Profit
Research & Development	$751.0K	$1.218M
YoY Change	-94.76%	-90.93%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.177M	$5.356M
YoY Change	-76.78%	-69.3%
Operating Profit	-$4.177M	-$5.303M
YoY Change	-302.47%	-65.81%
Interest Expense	$201.0K	$240.0K
YoY Change	-58.98%	-32.77%
% of Operating Profit
Other Income/Expense, Net	$386.0K	$171.0K
YoY Change	-339.75%	-400.0%
Pretax Income	-$3.590M	-$4.892M
YoY Change	-190.29%	-62.89%
Income Tax
% Of Pretax Income
Net Earnings	-$3.590M	-$4.900M
YoY Change	-190.29%	-62.88%
Net Earnings / Revenue		-9245.28%
Basic Earnings Per Share	-$2.76	-$3.95
Diluted Earnings Per Share	-$2.76	-$3.96
COMMON SHARES
Basic Shares Outstanding	1.320M	98.94M
Diluted Shares Outstanding	1.299M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.73M	$19.08M
YoY Change	-64.04%	-60.55%
Cash & Equivalents	$19.73M	$19.08M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$649.0K	$3.168M
YoY Change	-93.9%	-71.38%
Inventory
Prepaid Expenses
Receivables	$1.485M	$1.842M
Other Receivables	$137.0K	$2.332M
Total Short-Term Assets	$25.05M	$29.50M
YoY Change	-62.31%	-51.25%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$25.05M	$29.50M
Total Long-Term Assets	$0.00	$0.00
Total Assets	$25.05M	$29.50M
YoY Change	-71.38%	-64.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$969.0K	$1.518M
YoY Change	-87.26%	-73.98%
Accrued Expenses	$4.364M	$5.680M
YoY Change	-49.17%	-41.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.346M	$7.533M
YoY Change	-81.54%	-82.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.346M	$7.533M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$6.346M	$7.533M
YoY Change	-86.51%	-88.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$323.4M	-$319.9M
YoY Change	7.94%	5.37%
Common Stock	$1.000K	$1.000K
YoY Change	-98.99%	-98.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.71M	$21.96M
YoY Change
Total Liabilities & Shareholders Equity	$25.05M	$29.50M
YoY Change	-71.38%	-64.14%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$3.590M	-$4.900M
YoY Change	-190.29%	-62.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.480M	-$6.996M
YoY Change	-88.98%	-36.38%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$2.176M	$9.000M
YoY Change	-267.51%	-24.69%
Cash From Investing Activities	$2.176M	$9.000M
YoY Change	-259.3%	-24.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-1.480M	-$6.996M
Cash From Investing Activities	2.176M	$9.000M
Cash From Financing Activities	0.000
Net Change In Cash	696.0K	$1.688M
YoY Change	-86.04%	52.48%
FREE CASH FLOW
Cash From Operating Activities	-$1.480M	-$6.996M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$1.480M	-$6.996M
YoY Change	-89.04%	-36.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	14200000	eur
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3750000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1236688
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1236688
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1236688
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15617
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-37471
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-0784346
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	225 Franklin Street, 26th Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2024Q1	dei	City Area Code CityAreaCode	857
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	246-8998
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	PIRS
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1320240
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19084000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17396000	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	8970000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1842000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	572000	usd
CY2024Q1	us-gaap	Grants Receivable Current GrantsReceivableCurrent	3071000	usd
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	3141000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2332000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2326000	usd
CY2024Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	196000	usd
CY2023Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	2188000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2972000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4087000	usd
CY2024Q1	us-gaap	Assets Assets	29497000	usd
CY2023Q4	us-gaap	Assets Assets	38680000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1518000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3372000	usd
CY2024Q1	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	6015000	usd
CY2023Q4	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8550000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7533000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11922000	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	342165000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	341693000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-346000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	28000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319856000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314964000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	21964000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26758000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29497000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38680000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2010000	usd
CY2024Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	47000	usd
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	-74000	usd
CY2024Q1	us-gaap	Revenues Revenues	53000	usd
CY2023Q1	us-gaap	Revenues Revenues	1936000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1218000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13424000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4138000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4023000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	5356000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	17447000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5303000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15511000	usd
CY2024Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	240000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	357000	usd
CY2024Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	0	usd
CY2023Q1	us-gaap	Government Assistance Amount GovernmentAssistanceAmount	2028000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	171000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-57000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4892000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13183000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-373000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-242000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	70000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5266000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13355000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.95
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.15
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1237000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	931000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	27929000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13183000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	884000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-242000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	70000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15458000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26758000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4892000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	472000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-373000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	21964000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4892000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13183000	usd
CY2024Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-30000	usd
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	605000	usd
CY2024Q1	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	-0	usd
CY2023Q1	pirs	Operating Lease Right Of Use Asset Accretion OperatingLeaseRightOfUseAssetAccretion	34000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	472000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	884000	usd
CY2024Q1	pirs	Proceeds From Sale Of Fixed Assets Operating Activities ProceedsFromSaleOfFixedAssetsOperatingActivities	866000	usd
CY2023Q1	pirs	Proceeds From Sale Of Fixed Assets Operating Activities ProceedsFromSaleOfFixedAssetsOperatingActivities	0	usd
CY2024Q1	pirs	Noncash Adjustment Prepaid Rent NoncashAdjustmentPrepaidRent	556000	usd
CY2023Q1	pirs	Noncash Adjustment Prepaid Rent NoncashAdjustmentPrepaidRent	0	usd
CY2024Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-0	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-53000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-72000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	3963000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-607000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6996000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10996000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13495000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1544000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11903000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-316000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	200000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1688000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1107000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17396000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38635000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19084000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39742000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	70000	usd
CY2023Q3	pirs	Reduction In Workforce Percentage ReductionInWorkforcePercentage	0.70	pure
CY2023Q4	pirs	Reduction In Workforce Cost ReductionInWorkforceCost	7500000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	19100000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4900000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13200000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-319900000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Use of Estimates</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying unaudited condensed consolidated financial statements of Pieris Pharmaceuticals, Inc. and its wholly-owned subsidiaries were prepared in accordance with U.S. GAAP. The unaudited condensed consolidated financial statements include the accounts of all subsidiaries. All intercompany balances and transactions have been eliminated.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Effective at <em style="font: inherit;">5:00</em> p.m. Eastern Time on <em style="font: inherit;"> April 22, 2024, </em>the Company effected a <em style="font: inherit;">1</em>-for-80 reverse stock split of its common stock, or the Reverse Split, with any fractional shares resulting from the Reverse Split rounded up to the next whole share of common stock. All references to shares of common stock outstanding, average number of shares outstanding and per share amounts in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q have been restated to reflect the Reverse Split on a retroactive basis.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are <em style="font: inherit;">not</em> limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; beneficial conversion features; fair value of stock options, preferred stock, and warrants; fair value of assets held for sale; and prepaid and accrued clinical trial expenses. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q1	us-gaap	Revenues Revenues	53000	usd
CY2023Q1	us-gaap	Revenues Revenues	1936000	usd
CY2024Q1	pirs	Increase In Contract With Customer Liability IncreaseInContractWithCustomerLiability	0	usd
CY2024Q1	pirs	Decrease In Contract With Customer Liability DecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	pirs	Decrease In Contract With Customer Liability DecreaseInContractWithCustomerLiability	1700000	usd
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	17000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16064000	usd
CY2023Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	22194000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	usd
CY2024Q1	pirs	Longlived Assets Heldforsale Net Book Value LonglivedAssetsHeldforsaleNetBookValue	196000	usd
CY2023Q4	pirs	Longlived Assets Heldforsale Net Book Value LonglivedAssetsHeldforsaleNetBookValue	2188000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4190000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6448000	usd
CY2024Q1	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	719000	usd
CY2023Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	968000	usd
CY2024Q1	pirs	Accrued Accounts Payable Current AccruedAccountsPayableCurrent	549000	usd
CY2023Q4	pirs	Accrued Accounts Payable Current AccruedAccountsPayableCurrent	558000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	335000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	363000	usd
CY2024Q1	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	222000	usd
CY2023Q4	pirs	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	213000	usd
CY2024Q1	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	6015000	usd
CY2023Q4	pirs	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8550000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	500000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	600000
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3750000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1236688
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15617
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	13.34
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	0	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	0	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	288000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	186000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	0	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	474000	usd

Files In Submission

Name	View Source	Status
0001437749-24-017037-index-headers.html	Edgar Link	pending
0001437749-24-017037-index.html	Edgar Link	pending
0001437749-24-017037.txt	Edgar Link	pending
0001437749-24-017037-xbrl.zip	Edgar Link	pending
ex_638158.htm	Edgar Link	pending
ex_638159.htm	Edgar Link	pending
ex_638160.htm	Edgar Link	pending
ex_638161.htm	Edgar Link	pending
ex_672912.htm	Edgar Link	pending
ex_673179.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pirs-20240331.xsd	Edgar Link	pending
pirs-20240331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pirs-20240331_def.xml	Edgar Link	unprocessable
pirs-20240331_lab.xml	Edgar Link	unprocessable
pirs-20240331_pre.xml	Edgar Link	unprocessable
pirs20240331_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pirs20240331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2024 Q2 Form 10-Q Financial Statement

#000143774924017037 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2024 Q2 Form 10-Q Financial Statement

#000143774924017037 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs